Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 5/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CTSC | P53634 | 2/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2032501 | 0.99 | MMP2 (0.56) | MMP2ITGB3ITGA2BMMEACE | |
| SCHEMBL2032499 | 0.99 | MMP2 (0.56) | MMP2ITGB3ITGA2BMMEACE | |
| SCHEMBL16983210 | 0.99 | MMP2 (0.56) | MMP2ITGB3ITGA2BMMEACE | |
| SCHEMBL30051999 | 0.93 | CTSB (0.55) | MMP2ITGB3ITGA2BMMEACE | |
| SCHEMBL30051480 | 0.93 | CTSB (0.55) | MMP2ITGB3ITGA2BMMEACE | |
| SCHEMBL23142822 | 0.93 | CTSB (0.55) | MMP2ITGB3ITGA2BMMEACE | |
| SCHEMBL23142823 | 0.93 | CTSB (0.55) | MMP2ITGB3ITGA2BMMEACE | |
| SCHEMBL30439820 | 0.92 | OPRD1 (0.52) | ITGB3ITGA2BMMECTSBLMNA | |
| SCHEMBL30439797 | 0.92 | OPRD1 (0.52) | ITGB3ITGA2BMMECTSBLMNA | |
| SCHEMBL30997458 | 0.90 | QRFPR (0.54) | MMP2ITGB3ITGA2BMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698280-A1 | STABLE 4-ISOXAZOLINE CONJUGATES | Synaffix B.V. (NL) | 2026-02-25 | — | — | EP | disclosed |
| EP-4698231-A1 | CLEAVABLE IMMUNE CELL ENGAGERS | Synaffix B.V. (NL) | 2026-02-25 | — | — | EP | disclosed |
| US-20260021196-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | SYNAFFIX BV (NL) | 2026-01-22 | — | — | US | disclosed |
| EP-4658318-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | Synaffix B.V. (NL) | 2025-12-10 | — | — | EP | disclosed |
| US-20250367315-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | SYNAFFIX BV (NL) | 2025-12-04 | — | — | US | disclosed |
| EP-4637831-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | Synaffix B.V. (NL) | 2025-10-29 | — | — | EP | disclosed |
| US-20250312474-A1 | ANTHRACYCLINS AND CONJUGATES THEREOF | SYNAFFIX B.V. (NL) | 2025-10-09 | — | — | US | disclosed |
| EP-4572798-A1 | ANTHRACYCLINS AND CONJUGATES THEREOF | Synaffix B.V. (NL) | 2025-06-25 | — | — | EP | disclosed |
| EP-4556029-A2 | RADIOPHARMACEUTICAL CONJUGATE | The South African Nuclear Energy Corporation Limited (ZA) | 2025-05-21 | — | — | EP | disclosed |
| CN-119997985-A | Anthracyclines and conjugates thereof | 西纳福克斯股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024218162-A1 | CLEAVABLE IMMUNE CELL ENGAGERS | SYNAFFIX B.V. (NL) | 2024-10-24 | — | — | WO | disclosed |
| EP-4450489-A1 | STABLE 4-ISOXAZOLINE CONJUGATES | Synaffix B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| EP-4450093-A1 | CLEAVABLE IMMUNE CELL ENGAGERS | Synaffix B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024160926-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | SYNAFFIX B.V. (NL) | 2024-08-08 | — | — | WO | disclosed |
| EP-4410313-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | Synaffix B.V. (NL) | 2024-08-07 | — | — | EP | disclosed |
| WO-2024133815-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | SYNAFFIX B.V. (NL) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389152-A1 | CONJUGATES OF PBD PRODRUGS | Synaffix B.V. (NL) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024038065-A1 | ANTHRACYCLINS AND CONJUGATES THEREOF | SYNAFFIX B.V. (NL) | 2024-02-22 | — | — | WO | disclosed |
| US-11807899-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited | 2023-11-07 | — | — | US | disclosed |
| US-20220145378-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021196-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | FCGR2A, FCGR3B, FCGR1A | MMP2 3313/4885ITGB3 189/4885ITGA2B 104/4885 |
| US-20250312474-A1 | ANTHRACYCLINS AND CONJUGATES THEREOF | ANTXR2, NCL, DUT | MMP2 3174/4885ITGB3 1059/4885ITGA2B 324/4885 |
| US-20250367315-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | CD22, PBDC1, PA2G4 | MMP2 4186/4885ITGB3 427/4885ITGA2B 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.